- Passage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights
- Passage Bio to Participate in Upcoming Investor Conferences
- Passage Bio to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
- Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities
- Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
- Passage Bio Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights
- Passage Bio to Present at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology Conference
- Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Passage Bio to Present at Chardan’s 7th Annual Genetic Medicines Conference
- Passage Bio Reports Second Quarter 2023 Financial Results and Provides Recent Business Highlights
More ▼
Key statistics
On Friday, Passage Bio Inc (PASG:NSQ) closed at 1.15, 99.97% above the 52 week low of 0.5751 set on Nov 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.20 |
---|---|
High | 1.20 |
Low | 1.12 |
Bid | 1.10 |
Offer | 1.26 |
Previous close | 1.20 |
Average volume | 144.50k |
---|---|
Shares outstanding | 61.61m |
Free float | 61.41m |
P/E (TTM) | -- |
Market cap | 73.93m USD |
EPS (TTM) | -1.87 USD |
Data delayed at least 15 minutes, as of Apr 19 2024 21:00 BST.
More ▼